Any cranberry product showed no clear difference in symptomatic, culture‐verified UTI Elderly men and women in… compared with placebo or control (moderate certainty).
Any cranberry product probably leads to lower symptomatic, culture‐verified UTI Children compared with placebo or control (moderate certainty).
Any cranberry product showed no clear difference in symptomatic, culture‐verified UTI Adults with bladder emptying… compared with placebo or control (low certainty).
Any cranberry product may leads to lower symptomatic, culture‐verified UTI People with a susceptibility to a… compared with placebo or control (low certainty).
Any cranberry product showed no clear difference in gastrointestinal adverse events compared with placebo or control (moderate certainty).
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
Standard interferon showed no clear difference in death compared with placebo or control (low certainty).
Standard interferon showed no clear difference in relapse(recurrence after stopping intervention) compared with placebo or control (low certainty).
Standard interferon probably leads to higher end‐of‐treatment response compared with placebo or control (moderate certainty).
The review found no eligible studies for this question.
Standard interferon showed no clear difference in sustained virological response 6 months after stopping treatment compared with placebo or control (moderate certainty).
The review found no eligible studies for this question.
Direct antivirals (grazoprevir and elbasvir) may leads to higher end‐of‐treatment response compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.